News
-
-
PRESS RELEASE
Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F
Inventiva files its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F with the AMF and SEC. Documents accessible on Inventiva's website and regulatory authorities' sites -
-
PRESS RELEASE
Inventiva reports its 2024 full year results and provides a business update
Inventiva reports its 2024 full year financial results with revenues of €9.2 million, cash equivalents of €96.6 million and a structured financing of up to €348 million. Significant progress in the NATiV3 Phase 3 trial of lanifibranor for MASH. Pipeline prioritization plan presented -
-
-
-
PRESS RELEASE
Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment
Inventiva announces publication in Biomedicine & Pharmacotherapy of preclinical study results indicating lanifibranor's effectiveness in improving portal hypertension, potentially addressing complications of chronic liver diseases -
-
PRESS RELEASE
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
Inventiva and Hepalys Pharma, Inc. initiate clinical development program of lanifibranor in Japan with dosing of first participant in Phase 1 trial, marking significant progress in partnership
